Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in MTC and 131I-Refractory DTC
NCT00784303Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lenvatinib in Medullary Thyroid Cancer (MTC), differentiated thyroid cancer (DTC), sponsored by Eisai Co., Ltd.. Started Nov 2008; status: completed.
02
Drugs
lenvatinib
03
Conditions
Medullary Thyroid Cancer (MTC)differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT00784303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784303.